Cordlife (P8A.SI) S$0.13 pre-market 07 Jan 2026: Oversold bounce, watch RSI
The P8A.SI stock sits at S$0.13 in the SES pre-market on 07 Jan 2026, trading at its year low and showing an RSI of 26.88. This reading flags an oversold condition that can trigger a short-term bounce back toward the 50-day average at S$0.15. Volume is thin today, so any bounce needs confirmation from rising trade and a move above the 50-day average.
P8A.SI stock quick snapshot
Cordlife Group Limited (P8A.SI) trades on the SES in Singapore at S$0.13. The company market cap is S$33,320,007.00 and shares outstanding are 256,307,744. The stock is at its year low of S$0.13 with 50-day and 200-day averages at S$0.15 and S$0.20 respectively.
Why an oversold bounce matters for P8A.SI stock
Technical indicators show an oversold setup that can prompt a recovery trade. The RSI 26.88 and Stochastic %K at 4.44 point to short-term exhaustion. The Bollinger lower band sits near S$0.11, which supports a contained downside risk if buyers step in.
Fundamentals and valuation for P8A.SI stock
Cordlife operates in Medical – Diagnostics & Research across Asia and reports EPS -0.05 and a trailing PE of -2.60. The company holds S$0.20 cash per share and book value per share is S$0.44, giving a low P/B of 0.30. For more on Cordlife, see the company site and market data Cordlife website and the equity page on Investing.com source.
Technical setup, Meyka grade and short-term targets for P8A.SI stock
Price sits at strong short-term support at S$0.13 and needs follow-through volume to validate a bounce. Meyka AI rates P8A.SI with a score out of 100: 55.15 / C+ (HOLD). This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects yearly S$0.1122, implying -13.60% vs current price; forecasts are model-based and not guarantees.
Risks, liquidity and sector context for P8A.SI stock
Cordlife shows weak profitability with net margin -29.53% and long receivables days of 255. Average daily volume is low at 15,767, raising execution risk for larger trades. The Healthcare sector in Singapore is up 21.92% YTD, while Cordlife’s shorter-term price trends lag that sector performance.
Trading plan and price targets for P8A.SI stock
For an oversold bounce trade, consider a confirmation entry only after volume rises and price closes above S$0.15. Short-term resistance targets: S$0.15 (50-day), S$0.20 (200-day). A conservative stop sits below S$0.12 to limit downside. For internal tracking see our Meyka page Cordlife on Meyka.
Final Thoughts
P8A.SI stock at S$0.13 presents a classic oversold bounce setup on 07 Jan 2026 with RSI 26.88 and price at the year low. Fundamentals show cash per share S$0.20 and book value S$0.44, which provides balance-sheet support despite negative earnings. Meyka AI’s forecast model projects a yearly S$0.1122 (model-based), implying -13.60% versus today. A confirmed short-term trade requires rising volume and a clear close above S$0.15 with a first upside target near S$0.20. Note the stock’s low liquidity and stretched receivables as key risks. Use tight risk control and monitor healthcare sector moves for catalyst alignment.
FAQs
The stock shows an **RSI of 26.88** and trades at **S$0.13**, near strong balance-sheet support with **S$0.20 cash per share**, making a short-term bounce plausible if volume picks up.
Short-term resistance lies at the **50-day S$0.15** and the **200-day S$0.20**. A move above S$0.15 with rising volume would validate a next target toward S$0.20.
Meyka AI rates P8A.SI with a score out of 100 at **55.15 (C+, HOLD)** based on benchmark and sector comparisons, financials, metrics and forecasts; this is informational, not investment advice.
Key risks include thin liquidity (**avg vol 15,767**), negative net margin (**-29.53%**), long receivables (**255 days**), and reliance on regional demand in healthcare markets.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
